Pharmacological and clinical studies on the effects of angiotensin-converting enzyme (ACE) inhibitors support the idea of a central role played Angiotensin II which is able to cause cardiovascular and renal diseases also independently of its blood pressure elevating effects. The present investigation was aimed at evaluating the effect(s) of three different pharmacological regimens on both blood pressure and sympathetic drive in uncomplicated essential hypertension, by means of blood pressure laboratory measurements and ambulatory monitoring, 24-h heart rate variability and plasma noradrenaline levels. Thus, an ACE-inhibitor monotherapy (trandolapril, 2 mg/day), an AT 1 -receptor antagonist monotherapy (irbesartan, 300 mg/day), their low-dose combination (0.5 mg/day plus 150 mg/day, respectively) and placebo were given, in a randomised, single-blind, crossover fashion for a period of 3 weeks each to 12 mild essential hypertensives. Power spectral analysis (short recordings) and noradrenaline measurements
Introduction
A growing body of evidence from pharmacological and clinical studies on the effects of angiotensinconverting enzyme (ACE) inhibitors supports the notion that Angiotensin II (Ang II) may play a central role in the pathophysiology of hypertension and that it directly causes cardiovascular and renal diseases independently of its blood pressure elevating effect. [1] [2] [3] The sympathetic nervous system is also influenced by Ang II which, via the AT 1 receptor, is known to facilitate the release of cardiac sympathetic nerve terminals. 4, 5 In fact, in situ and in vitro studies in dogs demonstrated that Ang II enhances cardiac myocyte function via AT 1 receptor present in intrinsic adrenergic neurons. 6 Moreover, in Ang II-infused rats, surgical cardiac sympathectomy or treatment with atenolol, a ␤ 1 -adrenergic receptor blocker, significantly prevented cardiac myocyte necrosis, showing that Ang II cardiac damage is at least in part mediated by catecholamine release from cardiac sympathetic neurons. 7 In rats, it has been demonstrated that ACEinhibition does not influence the net catecholamine overflow during the stimulation of the sympathetic nerves. 2, 8, 9 This effect could be explained by a compensating mechanism of bradykinin, which may accumulate during ACE-inhibition, so stimulating catecholamine release via ␤ 2 -pre-synaptic receptors. 8, 9 It has also been demonstrated that AT 1 antagonism, while specifically and dose-dependently diminished noradrenaline and adrenaline release in animals, 9 had no effect on total body noradrenaline appearance rate in healthy humans. 10 So far, few studies 11, 12 have been performed to evaluate the effects of ACE-inhibitors and of AT 1 -antagonists on the sympathetic tone in hypertensives, but it has been difficult to demonstrate any favourable modulation of the autonomic nervous system in response to these agents. De Champlain et al 11 assessed haemodynamic and autonomic effects of trandolapril in hypertensive patients and observed that ACE inhibition did not affect heart rate and plasma noradrenaline levels, thus suggesting a blunted baroreflex response to the decrease in blood pressure. Giattanasio et al 12 found that the sympathetic vasoconstriction was attenuated by benzepril (as well as by captopril) suggesting that this effect, mainly operating during an increased sympathetic drive, was likely to be a class rather than a compound-related feature. Rongen et al 10 addressed the influence of short-term administration of losartan on sympathetic tone in healthy young men, but no effects of the drug were documented since it caused a resetting of the baroreflex regulation. Worck et al 13 assessed whether losartan, a specific AT 1 receptor antagonist, affects medullary adrenaline secretion and muscolocutaneous noradrenaline release during insulin-induced hypoglycaemia in man and found that, after drug administration, absolute values and time course changes in arterial glucose, arterial adrenaline, forearm musculocutaneous adrenaline release and heart rate were independent of AT 1 receptor blockade.
While ACE-inhibitors and AT 1 -antagonists are widely employed in the treatment of hypertension, there are so far theoretical reasons 14 to suggest that these two classes of drugs should also be used in combination.
The present investigation was aimed at evaluating and comparing the effect(s) of three different pharmacological regimens on blood pressure as well as sympathetic drive in uncomplicated essential hypertension, by means of blood pressure measurements, ambulatory blood pressure monitoring, 24-h heart rate variability and plasma noradrenaline levels. In particular, power spectral analysis and noradrenaline measurements were performed both at rest and after a postural challenge (head-up tilting). Thus, placebo, ACE-inhibitor monotherapy (trandolapril), AT 1 -receptor antagonist monotherapy (irbesartan) and their low-dose combination were randomly given to a group of mild essential hypertensives.
Methods

Protocol of the study
The study population was made up of 12 outpatients (six females, mean age 42 ± 4 years), with uncomplicated mild essential hypertension, according to the JNC VI. 15 Secondary hypertension was excluded by clinical history, physical examination, laboratory tests and excretory urogram or captopril scintigraphy. None had diabetes, cardiac, pulmonary, or renal diseases. All patients were in the sinus rhythm. Previous medications, if any, were discontinued at least 1 month before the study. Patients smoking more than five cigarettes a day were not included in the study. In all a transthoracic echocardiogram and a 24-h urine collection were performed in order to measure left ventricular mass 16, 17 and microalbuminuria. All patients gave their informed written consent to participate in the study, which was approved by the local Ethics Committee.
In a single-blind, crossover, random-order study design, patients were randomised to a 3-week period of therapy with trandolapril (2 mg/day), irbersartan (300 mg/day), their low-dose combination (trandolapril 0.5 mg/day and irbesartan 150 mg/day) and placebo. An order effect was excluded by giving drugs in random order. A 3-week washout period was carried out between the different medications. At the end of this period, that is before starting the drug regimen (at 3 pm), blood pressure was measured as previously 18 described. All subjects were instructed to avoid beverages containing alcohol or caffeine after 10 pm of the day preceding the study.
24-h ECG Holter recording and ambulatory blood pressure monitoring
At the end of each treatment period, a 24-h ECG Holter (ELA Medical, Segrate, Italy) recording and an ambulatory blood pressure 24-h monitoring (Spacelab, Redmond, WA, USA) were performed, and the following day all patients underwent a 60°h ead-up tilting test (HUT) as previously described.
18
24-h heart rate variability evaluation Heart rate variability (HRV) was evaluated in the time and frequency domains using a software provided by ELA medical (HRV module for ELATEC 1.0, ELA Medical, Segrate, Italy). 18 In the time domain, we considered the 24-h standard deviation of all RR intervals (24h-SDNN), an index of the overall variability, and the 24-h percentage of two consecutive RR with a difference superior to 50 ms (pNN50), which is a measure of high-frequency, vagally mediated HRV. 19 The following 24-h frequencydomain indexes were determined: (1) the lowfrequency (24h-LF) component, that is the value of the power (ms 
18,19
Power spectral analysis (short recordings) and blood pressure monitoring during 60؇ HUT On the following day, between 2 and 4 pm, headup tilting test was carried out in a dimly lit and quiet room, at a comfortable controlled temperature. After 30-min resting position (equilibration period) data were recorded for 15 min in the supine position and for 15 min in the 60°head-up tilted position. The study was not performed at a fixed respiration rate since it is difficult to maintain for such a long period (15 min). Basal blood pressure was automatically measured (Dinamap, Critikon, Tampa, FL, USA) every 3 min for 15 min in the resting position, after 30 min equilibration. Data were analysed on-line after appropriate analog-to-digital conversion at a rate of 300 samples per second per channel using a 12 bit converter (Data Translation), using the autoregressive methods according to Baselli et al. 20 Two major oscillatory components are usually detectable in RR variability: 14, 15, 18 the first one (HF), synchronous with respiration, has a frequency around 0.25 Hz, the second one (LF) has a frequency of about 0.1 Hz. The LF and HF components were expressed in absolute values as well as in normalised units (nu), as recommended by the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology
19
: normalisation was obtained by dividing each component by the total power, minus the power of the HRV below 0.03 Hz, and multiplying this ratio by 100. [21] [22] [23] [24] [25] Heart rate variability was performed and analysed by an author who was unaware of the patient's background.
Noradrenaline measurements
Blood samples for noradrenaline measurements were obtained at the end of both the supine and the tilted periods through a cannula, preventively inserted in an antecubital vein. Blood samples (3 ml) for noradrenaline determinations were collected in ice-chilled tubes containing 100 l solution of glutathione (60 mg/ml) and EGTA (90 mg/ml). Samples were centrifuged at 3000 rpm at 4°C and plasma was stored at −80°C until further processing. Noradrenaline was measured using a commercial kit (CAT-A-KIT, Amersham, Buckinghamshire, UK), as previously reported. 26 
Statistical analysis
Data are reported as mean ± s.d. Basal power spectral indexes and ambulatory blood pressure monitoring data were analysed by ANOVA, followed by Bonferroni t-test. Power spectral indexes behaviour, central low and high frequencies during tilt, and noradranaline levels were analysed by means of repeated measures two-way analysis of variance. A P value less than 0.05 was considered significant. ) and microalbuminuria (37 ± 5 mgm/day). At the beginning of each treatment period blood pressure values did not significantly differ, showing the absence of a carry-over effect (placebo: 152 ± 9/95 ± 8, trandolapril: 152 ± 9/96 ± 5, irbesartan: 153 ± 6/98 ± 5, combined therapy: 150 ± 5/98 ± 5 mm Hg).
Results
All
Heart rate variability (24-h recording) and ambulatory blood pressure monitoring Table 1 shows the values of mean arterial pressure and HRV parameters (both in the time and in the frequency domain). The administration of trandolapril, irbesartan ant their low-dose association caused a similar significant reduction in mean arterial pressure in the 24-h as well as in the daytime and night time periods. A significant reduction in LF/HF ratios (24 h, daytime and night time) was observed after both treatments with trandolapril or irbesartan, respectively, and this reduction was even greater after the low-dose combined therapy with respect to trandolapril alone (P = 0.047) and to irbesartan alone (P = 0.018). Absolute values of spectral components (24 h, daytime and night time) did not show any significant change induced by drug regimen. Similarly, no differences were observed in the 24-h time domain parameters of HRV (pNN50 and SDNN) after drug treatments in comparison with placebo.
Heart rate variability (short recordings), blood pressure values and noradrenaline plasma values during HUT
As depicted in Figure 1 , ANOVA analysis of power spectral values showed that drug therapy induced a significant reduction in supine values of LF (nu) (F = 5.417, P = 0.003), HF (nu) (F = 2.816, P = 0.050), and LF/HF ratio (F = 2.854, P = 0.048). Noteworthy, the combined low-dose therapy induced the greatest reduction in LF(nu) values and in LF/HF ratios measured in the supine position. No significant change after drug therapy was observed in HF component when expressed in absolute units whereas the combined therapy induced a significant reduction in LF also when expressed in absolute units.
As shown in Figure 2 and Table 2 , at the end of each regimen period, the reduction in systolic (SBP) and diastolic blood pressure (DBP) in baseline condition was significant for each treatment, but the combined low-dose therapy induced the greatest reduction in blood pressure values.
In the absence of drug therapy, the 60°HUT caused an increase in LF(nu) and a decrease in HF(nu) components, so that the LF/HF ratio increased. During drug therapy (both with irbesartan and trandolapril, as well as with their low-dose association), the HUT manoeuver was still able to induce a relative increase in LF component (expressed both in normalised and in absolute values), and in LF/HF ratio, but the behaviour of power spectral parameters (both in normalised and in absolute units) during tilt was independent of the kind of drug therapy. Table 2 also shows plasma values of noradrenaline observed in the supine position and during HUT during placebo and at the end of each treatment period. In the supine position irbesartan administration induced a significant increase in noradrenaline levels, while the low-dose combined therapy cause a significant decrease in its concentrations when compared with those observed during trandolapril and irbesartan treatment, respectively. The tilt manoeuver caused different changes for Table 2 Blood pressure values, power spectral indexes (normalised and absolute units) and noradreraline plasma levels in the supine position and during 60°head-up tilting (HUT) at the end of each period of treatment in the 12 patients with essential hypertension included in the study each drug regimen with a greater increase after irbesartan treatment (114%) than after the low-dose association treatment (84%). Table 3 shows the central frequencies of LF and HF bands evaluated in the supine position and during HUT performed after placebo as well as at the end of each regimen period. In each study period, the tilting manoeuver induced a leftward shift in the HF central frequency and no significant change in the LF central one. However, no drug effect on the central frequencies of spectral components was observed.
Discussion
Heart rate variability is a generally accepted noninvasive tool to assess cardiac autonomic function. 15, 18, 19, 21, 22 When analysed on 24-h ECG recordings, it allows the assessment of the cardiac autonomic profile during daily activities by the calculation of time-and frequency-domain parameters (Fast Fourier Trasform). 16, 17 In the present investigation, both trandolapril and irbesartan at therapeutical doses, equally effective in Table 3 Central frequencies of LF and HF in the supine position and during 60°head-up tilting (HUT) at the end of each period of treatment in the 12 patients with essential hypertension included in the study The main finding of the present study is however that the low-dose combined therapy (ACE inhibitor and AT 1 antagonist), when compared with the recommended dose monotherapy, induced, together with a greater reduction in blood pressure, a more significant decrease in the LF component (both expressed in normalised and absolute units) in the resting position, the physiological response to the postural challenge being maintained. A reduction in LF/HF ratios, as an expression of relative lower sympathetic tone, was also documented in the 24-h recordings as well as in the daytime and night time periods. These findings are in agreement with those by Pancera et al 27 who documented that there was a significant reduction in the LF power component after the administration of losartan in hypertensives. On the contrary, they differ from those by Rongen et al 10 who did not document any influence on sympathetic tone by short-term administration of losartan. This discrepancy may be due to several factors: the different population included (essential hypertensives vs healthy subjects), the different period of treatment (3 weeks vs 1 week) and the different methodology employed (autoregressive algorithm vs Fast Fourier Transformation).
Few papers have investigated the effects of ACEinhibitor and AT 1 -antagonist low-dose combined therapy both in cardiac failure and in essential hypertension. In patients with severely symptomatic heart failure 28,29 the addition of an angiotensin II receptor antagonist to an ACE inhibitor significantly improved the exercise tolerance. In the RESOLVD pilot study, 30 the combination of both drugs did not produce an incremental reduction in plasma catecholamine levels in comparison with that obtained with either ACE-inhibition or AT 1 -antagonism alone. However, the progressive left ventricular enlargement was delayed or even reversed in the combined treatment groups, even though no significant differences in mortality between combined therapy and monotherapy were documented.
In the present study, the possible reductive influence on the cardiac sympathetic drive induced by the low-dose combined therapy could be related to a more efficacious and multilevel blockade of the renin-angiotensin system. Indeed, because of the pharmacokinetic properties of ACE inhibitors and the possibility that angiotensin II is also generated by non-ACE pathways, 14 the AT 1 antagonists, through their action at the receptor level, warrants a more complete block of the system, so providing a more specific approach in blocking the vascular effect of Ang II so relevant to hypertension. Moreover, since an increase in the Ang II concentrations has been described during irbesartan treatment, 31, 32 the association with an ACE-inhibitor could blunt this effect, so potentiating the antihypertensive efficacy of the receptor antagonist. A recent study in animals 33 compared the effects of combined AT 1 receptor antagonist (losartan) and ACE-inhibitor (enalapril) with those of high-dose monotherapy on blood pressure and cardiac weight. The authors documented a greater reduction in blood pressure and left ventricular mass after the combined therapy, together with lower values of circulating Ang II levels (particularly when compared with those observed with losartan alone).
In our study, the low-dose combined therapy also induced a slight reduction in noradrenaline plasma levels, suggesting that this regimen is able not only to decrease the cardiac sympathetic tone (as investigated by heart rate variability) but also to influence the systemic one. In fact, plasma noradrenaline levels mirror systemic sympathetic tone. 33 This phenomenon is intriguing but its interpretation is somewhat speculative since combined and opposite effects could be involved. While ACE-inhibition is known to scarcely affect noradrenaline levels, even through the compensating mechanism of bradykinin, 2, 8, 9 the influence of AT 1 antagonists on catecholamine balance is still debated and few data are available in humans. In this respect, some authors 2, 31 observed that these class compounds are able to enhance the release of noradrenaline by increasing the pre-synaptic Ang II levels and that Ang II-receptor antagonism may facilitate (rather than, as expected, reduce) the sympathetically mediated vasoconstriction in normal subjects. 34 Indeed, in the present investigation we documented a significant increase in noradrenaline levels after irbesartan treatment. On the contrary, no changes in noradrenaline concentrations were observed after trandolapril administration and these results are in agreement with the experimental ones by Raasch et al, 35 who showed that ACE-inhibition increased neuronal uptake of catecholamines in spontaneously hypertensive rats in a blood pressureindependent manner.
In the framework of our study protocol the evaluation of cardiac noradrenaline spillover might have been an useful tool in exploring the organ sympathetic activation, thus allowing to better interpret the results obtained with power spectral analysis. Unfortunately such a procedure is somewhat impractical for technical reasons during tilting.
In conclusion, the results of the present clinical investigation demonstrate that in mild and uncomplicated essential hypertension, the chronic lowdose combination therapy with an ACE-inhibitor (trandolapril) and an AT 1 -antagonist (irbesartan) is more effective than the full dose monotherapy with each drug in reducing blood pressure and influencing the autonomic drive to the heart, either in the resting position or after a sympathetic challenge (tilting manoeuver). Probably, where there is less Ang II around (due to ACE-inhibition) an AT 1 blocker can result in a better competitive antagonisms for AT 1 receptors. Further studies are needed to better clarify the potential role and the pathophysiological meaning of the dual, differential, blockade of the renin-angiotensin system in clinical settings. However, the finding that the low-dose combined therapy is probably able to obtain a lower relative cardiac sympathetic tone and a significant blood pressure decrease in the framework of a slight reduction in systemic sympathetic nervous activity, remains an interesting clinical target in the treatment of essential hypertension. In fact, it is known 14 that most blood pressure lowering agents are able to reduce the incidence of stroke, but that the prevention of coronary events or the control of left ventricular hypertrophy is less readily and generally achieved. 36 One explanation for the relatively disappointing results in preventing coronary events with traditional therapies includes the observation that the high blood pressure is part of a syndrome of cardiovascular risk termed 'the hypertension syndrome' [37] [38] [39] in which an increased activity of both sympathetic nervous system and renin-angiotensin system plays a major role.
In this context, our data, though obtained in a small number of patients, are promising and deserve
